COPD(GENE): TASK B: "STEWARDSHIP OF BIOSPECIMEN AND DATA REPOSITORIES"

COPD（基因）：任务 B：“生物样本和数据存储库的管理”

• 批准号: 10974167
• 负责人: James D Crapo
• 金额: $ 92.54万
• 依托单位: NATIONAL JEWISH HEALTH
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-08-10 至 2024-08-09
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10974167
• 关键词: COPD; GENE; TASK; STEWARDSHIP; BIOSPECIMEN

Chronic obstructive pulmonary disease (COPD) is a syndrome commonly defined by a single physiological feature–chronic airflow obstruction. To improve diagnosis and treatment of COPD, it is essential to divide this complex syndrome into biologically meaningful subgroups of COPD patients and to predict disease progression accurately within those subtypes. Our primary approaches to assess COPD progression will use physiology (i.e., FEV1 decline) and imaging (i.e., increased emphysema); however, we will also assess clinical characteristics (e.g., increased exacerbations) and epidemiology (e.g., increased mortality). We will apply imaging, physiology, epidemiology, transcriptomics, proteomics, metabolomics, epigenetics, and genetics to a 15-year longitudinal cohort of smokers to provide new insights into COPD progression. Longitudinal analysis of physiological and imaging data will provide valuable information regarding progression (or stability) of airflow obstruction, CT measurements of emphysema and airway disease, and clinical characteristics. Longitudinal analysis of Omics data will identify biomarkers of COPD progression within disease subtypes. Machine learning and network analysis of multiple Omics data will implicate pathobiological mechanisms for COPD progression. Genetic association analysis using existing whole genome sequencing (WGS) data will identify both rare and common genetic determinants of COPD progression. Integrating WGS with RNA-Seq, DNA methylation, metabolomics, and proteomics will also facilitate identification of functional variants within regions of genetic association.

慢性阻塞性肺疾病（COPD）是一种通常由单一生理特征-慢性气流阻塞定义的综合征。为了改善COPD的诊断和治疗，将这种复杂的综合征分为具有生物学意义的COPD患者亚组并准确预测这些亚型内的疾病进展至关重要。我们评估COPD进展的主要方法将使用生理学（即，FEV 1下降）和成像（即，增加的肺气肿）;然而，我们还将评估临床特征（例如，加重增加）和流行病学（例如，死亡率上升）。我们将应用影像学、生理学、流行病学、转录组学、蛋白质组学、代谢组学、表观遗传学和遗传学对15年的吸烟者纵向队列进行研究，以提供对COPD进展的新见解。对生理和成像数据的纵向分析将提供关于气流阻塞的进展（或稳定性）、肺气肿和气道疾病的CT测量以及临床特征的有价值的信息。组学数据的纵向分析将确定疾病亚型内COPD进展的生物标志物。多个组学数据的机器学习和网络分析将涉及COPD进展的病理生物学机制。使用现有的全基因组测序（WGS）数据进行的遗传关联分析将识别COPD进展的罕见和常见遗传决定因素。将WGS与RNA-Seq、DNA甲基化、代谢组学和蛋白质组学相结合也将有助于识别遗传相关区域内的功能变体。